pexastimogene devacirepvec

AXP000011.2 · Oncolytic virus

Platform
vaccinia virus (Wyeth strain, thymidine kinase-deleted)
Originator
Jennerex
Sponsor
SillaJen

Names

NameTypeSource
pexastimogene devacirepvecpreferred name, INNcurator, ncit
JX-594codencit
TG-6006codencit
Pexa-Vecsynonymncit

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
Wyeth
Replication
conditionally replicating
Modifications
J2R (thymidine kinase) disrupted by the transgene cassette
Transgenes
CSF2, LacZ
Route
intratumoral, intravenous
Source
evidence

Cross-references

NCI Thesaurus
C71533
Wikidata
Q3816624
FDA UNII
K82DG47I0G

Approvals

No regulatory approval recorded.

Clinical trials (20)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04849260Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic MelanomaUnknownPhase 1/22021-08-262022-05-3154Local Progression or Metastatic Melanoma With Failed First-line Treatment
NCT03294083A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell CarcinomaCompletedPhase 1/22018-06-192023-02-1695Renal Cell Carcinoma
NCT03206073A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerCompletedPhase 1/22017-12-072020-09-2434Colorectal Adenocarcinoma; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Refractory Cancer
NCT03071094A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)TerminatedPhase 1/22017-07-272020-09-3014Hepatocellular Carcinoma (HCC)
NCT02977156Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.CompletedPhase 12017-01-032022-04-1322Advanced Tumor; Metastatic Tumor
NCT02562755Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib AloneCompletedPhase 32015-102020-07459Hepatocellular Carcinoma (HCC)
NCT02630368A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)UnknownPhase 1/22015-09-182023-05197Breast Cancer; Soft-tissue Sarcoma; Solid Tumors
NCT02017678Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer OriginWithdrawnPhase 22014-012015-010Ovarian Cancer
NCT01636284A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver CancerCompletedPhase 22012-062013-0616Hepatocellular Carinoma
NCT01394939Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal CarcinomaCompletedPhase 1/22012-012015-0652CRC; Colorectal Carcinoma
NCT01387555A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed SorafenibCompletedPhase 22011-10-082013-10-01129HCC; Hepatocellular Carcinoma; Liver Cancer
NCT01329809Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver ResectionTerminatedPhase 22011-102012-012Colorectal Carcinoma
NCT01380600Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal CarcinomaCompletedPhase 12010-09-082012-10-1815Carcinoma, Colorectal
NCT01169584Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric PatientsCompletedPhase 12010-082012-036Ewing's Sarcoma; Lymphoma; Neuroblastoma; Rhabdomyosarcoma; Wilm's Tumor
NCT01469611A Trial of JX-594 in Refractory Colorectal CarcinomaCompletedPhase 12010-072012-1015Colorectal Carcinoma
NCT01171651A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular CarcinomaCompletedPhase 22009-05-262012-09-2725Carcinoma, Hepatocellular
NCT00554372A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular CarcinomaCompletedPhase 22008-082011-1230Carcinoma, Hepatocellular
NCT00625456Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid TumorsCompletedPhase 12008-062010-0423Lung Cancer; Melanoma; Renal Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck
NCT00429312A Study of Recombinant Vaccinia Virus to Treat Malignant MelanomaCompletedPhase 1/22007-022008-0210Melanoma
NCT00629759A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic CarcinomaCompletedPhase 12006-012007-0714Neoplasms, Liver

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42603198Liver Transplantation Following Hepatocellular Carcinoma Rupture and Long-Term Immunotherapy: A Case Report.Journal of gastrointestinal cancer2026name in abstract: Pexa-Vec
PMID 38378555Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.Molecular cancer2024name in title: JX-594
PMID 36754451Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.Journal for immunotherapy of cancer2023cited by trial NCT03206073
PMID 36271420Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.Journal of hematology & oncology2022name in title: JX-594
PMID 31413923Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).Oncoimmunology2019cited by trial NCT01387555
PMID 25531693Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.Molecular therapy : the journal of the American Society of Gene Therapy2015name in title: Pexa-Vec
PMID 26072416A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.Methods in molecular biology (Clifton, N.J.)2015name in title: Pexa-Vec
PMID 26073886Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.Molecular therapy : the journal of the American Society of Gene Therapy2015name in title: Pexa-Vec
PMID 26471278Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma.BMC cancer2015name in title: JX-594
PMID 23393196Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.Cancer research2013cited by trial NCT00554372
PMID 23396206Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.Nature medicine2013cited by trial NCT00554372
PMID 23677592Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.Science translational medicine2013name in abstract: pexastimogene devacirepvec
PMID 21772252A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.Molecular therapy : the journal of the American Society of Gene Therapy2011name in title: JX-594
PMID 18495536Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.The Lancet. Oncology2008cited by trial NCT00629759
Unconfirmed matches (2)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 37384323Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis.Journal of liver cancer2020name in abstract: JX-594
PMID 21886163Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Nature2011name in abstract: JX-594

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42156493Oncolytic vaccinia virus JX-594 shows subtype-specific activity and candidate biomarkers in gastric cancer cell lines.Scientific reports2026name in title: JX-594
PMID 42456895Oncolytic viruses in cancer therapy: Mechanisms, challenges, and emerging clinical applications.Annales pharmaceutiques francaises2026name in abstract: Pexa-Vec
PMID 42636898Killing to cure: harnessing poxvirus-driven cell death for viral immunotherapy.Immunology letters2026name in abstract: pexastimogene devacirepvec
PMID 42837725Oncolytic viruses in gastrointestinal malignancies: Clinical progress, translational challenges, and future directions.Seminars in oncology2026name in abstract: pexastimogene devacirepvec
PMID 42909267Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling.Frontiers in cell and developmental biology2026name in abstract: Pexa-Vec
PMID 41228258The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management.Cancers2025name in abstract: Pexa-Vec
PMID 38756145PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.Liver cancer2024name in title: Pexa-Vec
PMID 38837373Gene therapy for people with hepatocellular carcinoma.The Cochrane database of systematic reviews2024name in abstract: pexastimogene devacirepvec
PMID 36717184Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.Journal for immunotherapy of cancer2023name in abstract: Pexa-Vec
PMID 36896445Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions.Asian journal of pharmaceutical sciences2023name in abstract: pexastimogene devacirepvec
PMID 35052851Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment.Biomedicines2022name in abstract: pexastimogene devacirepvec
PMID 35118189Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade.Molecular therapy oncolytics2022name in abstract: Pexa-Vec
PMID 35439304Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.Cancer immunology research2022name in abstract: pexastimogene devacirepvec
PMID 35453555Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8+ T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy.Biomedicines2022name in abstract: pexastimogene devacirepvec
PMID 35565310Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients.Cancers2022name in abstract: Pexa-Vec
PMID 36467495Progress of oncolytic virotherapy for neuroblastoma.Frontiers in pediatrics2022name in abstract: Pexa-Vec
PMID 36474303Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer.Experimental hematology & oncology2022name in title: JX-594
PMID 34332591Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.Virology journal2021name in abstract: pexastimogene devacirepvec
PMID 35116288The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.Translational cancer research2021name in abstract: Pexa-Vec
PMID 32162802Intratumoral Immunotherapy-Update 2019.The oncologist2020name in abstract: Pexa-Vec
PMID 32690442Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy.Cytokine & growth factor reviews2020name in abstract: Pexa-Vec
PMID 30462296Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.Japanese journal of clinical oncology2019name in abstract: pexastimogene devacirepvec
PMID 30626434Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.Journal for immunotherapy of cancer2019name in abstract: Pexa-Vec
PMID 31428674Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy.Molecular therapy oncolytics2019name in abstract: Pexa-Vec
PMID 28359239Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.Current cancer drug targets2018name in abstract: pexastimogene devacirepvec
PMID 27635026Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2017name in abstract: Pexa-Vec
PMID 27901484Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.Oncotarget2017name in abstract: Pexa-Vec
PMID 27451890Vacca pox to pexa vec: John Hunter's and Edward Jenner's contribution to oncolytic virotherapy.The Journal of surgical research2016name in title: Pexa-Vec
PMID 27486853Oncolytic virus therapy: A new era of cancer treatment at dawn.Cancer science2016name in abstract: pexastimogene devacirepvec
PMID 25807289Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.Molecular therapy : the journal of the American Society of Gene Therapy2015name in abstract: Pexa-Vec
PMID 25900822Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.Current opinion in virology2015name in title: Pexa-Vec
PMID 27512667The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).Oncolytic virotherapy2015name in title: Pexa-Vec
PMID 23836532New frontier in liver cancer treatment: oncolytic viral therapy.Hepatology (Baltimore, Md.)2014name in abstract: Pexa-Vec
PMID 24020520Oncolytic viruses as therapeutic cancer vaccines.Molecular cancer2013name in abstract: Pexa-Vec
PMID 21740365Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.Current pharmaceutical biotechnology2012name in title: JX-594
PMID 22186794The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.Molecular therapy : the journal of the American Society of Gene Therapy2012name in title: JX-594
PMID 21427706Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.Molecular therapy : the journal of the American Society of Gene Therapy2011name in title: JX-594
PMID 20808290Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.Molecular therapy : the journal of the American Society of Gene Therapy2010name in title: JX-594
PMID 19943208JX-594, a targeted oncolytic poxvirus for the treatment of cancer.Current opinion in investigational drugs (London, England : 2000)2009name in title: JX-594
PMID 18628758The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.Molecular therapy : the journal of the American Society of Gene Therapy2008name in title: JX-594
PMID 16905462Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.Molecular therapy : the journal of the American Society of Gene Therapy2006name in title: JX-594
Unconfirmed matches (20)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 40685482Oncolytic virotherapy and tumor microenvironment modulation.Clinical and experimental medicine2025name in abstract: JX-594
PMID 40856833BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy.Cancer immunology, immunotherapy : CII2025name in abstract: JX-594
PMID 41662640Review Article: Intratumoral Immunotherapy: Old Discoveries and Recent Developments in Sarcomas.Critical reviews in oncogenesis2025name in abstract: JX-594
PMID 38291394PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma.Cancer cell international2024name in abstract: JX-594
PMID 39598813Using Computer Modeling and Experimental Methods to Screen for Aptamers That Bind to the VV-GMCSF-LACT Virus.Molecules (Basel, Switzerland)2024name in abstract: JX-594
PMID 37749907Oncolytic virotherapies for pediatric tumors.Expert opinion on biological therapy2023name in abstract: JX-594
PMID 29259007Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.Cancer research2018name in abstract: JX-594
PMID 29900755Exploring the role of oncolytic viruses in hepatobiliary cancers.Immunotherapy2018name in abstract: JX-594
PMID 28496337Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.OncoTargets and therapy2017name in abstract: JX-594
PMID 26803055Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.Cancer letters2016name in abstract: JX-594
PMID 25711964Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.The Journal of general virology2015name in abstract: JX-594
PMID 24502935Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses.The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland2014name in abstract: JX-594
PMID 23433318Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.Orphanet journal of rare diseases2013name in abstract: JX-594
PMID 23824333Live viruses to treat cancer.Journal of the Royal Society of Medicine2013name in abstract: JX-594
PMID 21338330Oncolytic vaccinia virus for the treatment of cancer.Expert opinion on biological therapy2011name in abstract: JX-594
PMID 22102388Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines.The Korean journal of hepatology2011name in abstract: JX-594
PMID 20472490Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.Cytokine & growth factor reviews2010name in abstract: JX-594
PMID 20852754Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2010name in abstract: JX-594
PMID 19798455Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2009name in abstract: JX-594
PMID 18850047Gateways to clinical trials. July-August 2008.Methods and findings in experimental and clinical pharmacology2008name in abstract: JX-594

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC011343Clinical protocols for the treatment of gastrointestinal cancerDIVISION OF BASIC SCIENCES - NCIGRETEN, TIM2019–2023name in abstract: Pexa-Vec
DP2CA195764Oncolytic Virotherapy in Hepatocellular CancerMAYO CLINIC ARIZONABORAD, MITESH2014–2016name in abstract: Pexa-Vec

Notes

Jennerex acquired by SillaJen in 2014; Transgene was a partner and used the code TG-6006. Not the same product as TG6002, a different Transgene vaccinia construct. Transgenes moved from targets to virus.tsv (spec 0.2).

How to cite

pexastimogene devacirepvec (AXP000011.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000011.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.